Core Viewpoint - BiomX Inc. has announced a private placement financing expected to raise approximately $3.0 million to support its bacteriophage programs and evaluate strategic alternatives [1][7]. Group 1: Private Placement Details - The private placement involves the issuance of Series Y Convertible Preferred Stock with a stated value of $1,000 per share, along with warrants, for a total purchase price of $3.0 million [3]. - Each share of Series Y Convertible Preferred Stock will accrue dividends at a rate of 15% per annum, payable quarterly, and has a maturity of one year from the closing date [4]. - The company will issue warrants to acquire up to 3,300,000 shares of common stock, with an initial exercise price of $2.00 and a five-year term [5]. Group 2: Use of Proceeds - The net proceeds from the private placement will be used to assess opportunities in the company's bacteriophage programs, particularly BX011 for Staphylococcus aureus infections related to diabetic foot infections, and for general corporate purposes [7]. Group 3: Regulatory and Closing Information - The securities sold in the private placement have not been registered under the Securities Act and were offered in reliance on exemptions from registration requirements [6]. - The private placement is expected to close on or about December 30, 2025, subject to customary closing conditions [5]. Group 4: Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies to target harmful bacteria for chronic diseases with significant unmet needs [9]. - The company utilizes its BOLT platform to customize phage compositions against proprietary bacterial targets [9].

Core Viewpoint - BiomX Inc. is set to host a conference call on May 15, 2025, to discuss its first quarter 2025 financial results and provide updates on its business and programs [1]. Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies aimed at targeting and eliminating specific pathogenic bacteria [3]. - The company utilizes its proprietary BOLT ("BacteriOphage Lead to Treatment") platform to customize phage compositions against validated bacterial targets [3].